Aquablation for benign prostatic obstruction: Single center technique evolution and experience

Muhieddine Labban; Mazen Mansour; Nicolas Abdallah; Rola Jaafar; Wassim Wazzan; Muhammad Bulbul; Albert El-Hajj

추천

검색

자료유형: 학술저널

저자정보: Muhieddine Labban (American University of Beirut Medical Center) Mazen Mansour (American University of Beirut Medical Center) Nicolas Abdallah (American University of Beirut Medical Center) Rola Jaafar (American University of Beirut Medical Center) Wassim Wazzan (American University of Beirut Medical Center) Muhammad Bulbul (American University of Beirut Medical Center) Albert El-Hajj (American University of Beirut Medical Center)

저널정보: 대한비뇨기과학회 Investigative and Clinical Urology Investigative and Clinical Urology Vol.62 No.2

발행연도: 2021.1

수록면: 210 - 216 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: Aquablation is a new technology that relies on real-time ultrasound guidance to ablate prostatic tissues using high velocity pressurized water. We hereby present our data and experience in this technique by exploring the perioperative surgical and functional outcomes. Materials and Methods: This is a prospectively filled study including consecutive patients who underwent aquablation at our Middle Eastern tertiary care center. Patient demographics, voiding parameters, and prostate disease specific variables were collected. We reported on the surgical and functional outcomes as well as the 3-month adverse events. We also explored the trend in hemoglobin drop and hemostasis method by dividing the consecutive cases into four temporal periods. Results: Fifty-nine patients underwent aquablation between March 2018 and March 2020. Mean time from transrectal ultrasound to Foley insertion was 48.5±2.5 minutes. Cautery was performed in 35 patients (59.3%) and a catheter-tensioning device was mounted in 50 patients (84.7%). On average, the hemoglobin dropped by −1.7±0.2 ng/dL (p<0.0001). The average length of catheterization and hospital stay were 2.1±0.3 days and 2.2±0.1 days, respectively. Only three patients (5.1%) were re-hospitalized. At three months, the average drop in serum prostate-specific antigen was −36.6±6.0% (p<0.0001) and functional outcomes considerably improved. We also recorded 14 adverse events in 13 patients (overall rate of 22.0%), with grade 1 and grade 2 complications comprising 71.4% of all adverse events. Conclusions: Our study results confirm the safety and efficacy of the aquablation procedure in the adoption phase.

#Lower urinary tract symptoms #Prostatic hyperplasia #Robotic surgical procedures #Therapy

참고문헌 (17)

참고문헌 신청

Lee SWH / 2017 / The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a systematic review and meta-analysis / Sci Rep 7:7984

Wu DB / 2018 / Economic evaluation of combination therapy versus monotherapy for treatment of benign prostatic hyperplasia in Hong Kong / Front Pharmacol 9:1078

Bach T / 2020 / First multicenter all-comers study for the Aquablation procedure / J Clin Med 9:603

Bach T / 2019 / Aquablation of the prostate : single-center results of a non-selected, consecutive patient cohort / World J Urol 37:1369~1375

Misrai V / 2019 / Waterjet ablation therapy for treating benign prostatic obstruction in patients with small-to medium-size glands : 12-month results of the first French aquablation clinical registry / Eur Urol 76:667~675

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!